QNRX - MCAP CO - Quoin Pharmaceuticals

Quoin Pharmaceuticals (QNRX) dominates the rare skin pathology therapy niche, possessing exceptional pricing power due to a lack of alternatives. This price trend chart, where the market capitalization stands at 0.01, confirms the company's position. The business relies on the development of treatments for Netherton syndrome, holding FDA orphan drug status and successful clinical trial results.

Strategic alliances of Quoin Pharmaceuticals (QNRX) in the field of dermatology are accelerating the commercialization of orphan drugs. The issuer's market capitalization aggregates the value of all shares, reflecting the total business valuation by investors. This chart captures the equilibrium points of supply and demand within the sector. Value consolidation confirms the company's fundamental stability as it prepares for new trends. Current indicator volatility determines the brand's investment attractiveness.